Compare Eli Lilly And Co (LLY) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sibanye Stillwater Ltd — how do they compare? Eli Lilly And Co trades at $1,173 (market cap $1.02T), while Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B). The key difference: Eli Lilly And Co is far larger — about 180.2× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| LLY | SBSW | |
|---|---|---|
Market Cap | $1.02T | $5.66B |
Sector | Health | Basic Materials |
52-Week High | $1.24K | $21.12 |
52-Week Low | $625.65 | $7.27 |
Enterprise Value | $1.06T | $7.28B |
Dividend Yield | 0.6% | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
SBSW trades at $8.59, up 7.38% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $7.30B in 2024 despite $112.13B revenue, though 2025 projections show improved EBITDA of $21.4B. Analyst consensus is mixed with 42.9% buy ratings and a $14.25 price target, representing 66% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with deep value characteristics (P/E 4.76, P/S 0.72) but faces significant execution risks amid negative ROE and ROA. Key catalysts include management's debt reduction targets and operational improvements, while commodity price volatility remains a major headwind for the mining company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
